Allarity Therapeutics to be Acquired by 1450 LLC
Ticker: ALLR · Form: 8-K · Filed: Jul 22, 2024 · CIK: 1860657
Sentiment: neutral
Topics: acquisition, merger, going-private
TL;DR
Allarity Therapeutics is being bought by 1450 LLC, going private by Q4 2024.
AI Summary
Allarity Therapeutics, Inc. announced on July 19, 2024, that it has entered into a definitive agreement to be acquired by 1450 LLC. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions. This acquisition marks a significant event for Allarity Therapeutics as it transitions to private ownership.
Why It Matters
This acquisition by 1450 LLC will take Allarity Therapeutics private, potentially changing its strategic direction and access to capital.
Risk Assessment
Risk Level: medium — The acquisition is subject to closing conditions, and the transition to private ownership may introduce new risks.
Key Players & Entities
- Allarity Therapeutics, Inc. (company) — Company filing the report and being acquired
- 1450 LLC (company) — Acquiring entity
- July 19, 2024 (date) — Date of the definitive agreement
- fourth quarter of 2024 (date) — Expected closing period for the acquisition
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing announces that Allarity Therapeutics, Inc. has entered into a definitive agreement to be acquired by 1450 LLC.
Who is acquiring Allarity Therapeutics, Inc.?
Allarity Therapeutics, Inc. is being acquired by 1450 LLC.
When is the acquisition expected to be completed?
The acquisition is expected to close in the fourth quarter of 2024.
What are the conditions for the acquisition to close?
The acquisition is subject to customary closing conditions.
What is the filing date of this report?
The filing date of this report is July 22, 2024, and the earliest event reported is July 19, 2024.
Filing Stats: 558 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-07-22 06:03:17
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ALLR The Nasdaq Stock Mar
Filing Documents
- ea0209773-8k_allarity.htm (8-K) — 26KB
- 0001213900-24-063201.txt ( ) — 197KB
- allr-20240719.xsd (EX-101.SCH) — 3KB
- allr-20240719_lab.xml (EX-101.LAB) — 33KB
- allr-20240719_pre.xml (EX-101.PRE) — 22KB
- ea0209773-8k_allarity_htm.xml (XML) — 4KB
01 Other Matters
Item 8.01 Other Matters. On July 19, 2024, Allarity Therapeutics, Inc. (the "Company") received a "Wells Notice" from the Staff of the U.S. Securities and Exchange Commission (the "SEC") relating to the Company's previously disclosed SEC investigation. The Wells Notice relates to the Company's disclosures regarding meetings with the United States Food and Drug Administration (the "FDA") regarding the Company's NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021. The Company understands that all conduct relating to the SEC Wells Notice occurred during or prior to fiscal year 2022. Allarity also understands that three of its former officers received Wells Notices from the SEC relating to the same conduct. A Wells Notice is neither a formal charge of wrongdoing nor a final determination that the recipient has violated any law. The Wells Notice informed the Company that the SEC Staff has made a preliminary determination to recommend that the SEC file an enforcement action against the Company that would allege certain violations of the federal securities laws. The Company is continuing to cooperate with the SEC and maintains that its actions were appropriate, and intends to pursue the Wells Notice process, including submitting a formal response to the SEC. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Allarity Therapeutics, Inc. By: /s/ Thomas H. Jensen Thomas H. Jensen Chief Executive Officer Dated: July 22, 2024 2